P/E ratio for Protalix BioTherapeutics (PLX)
P/E ratio as of June 2024 (TTM): 11.4
According to Protalix BioTherapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 11.4. At the end of 2022 the company had a P/E ratio of -4.57.
P/E ratio history for Protalix BioTherapeutics from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -4.57 | 241.12% |
| 2021 | -1.34 | -94.84% |
| 2020 | -25.9 | 880.23% |
| 2019 | -2.65 | 62.12% |
| 2018 | -1.63 | 61.54% |
| 2017 | -1.01 | -93.49% |
| 2016 | -15.5 | -194.32% |
| 2015 | 16.5 | -129.51% |
| 2014 | -55.8 | -57% |
| 2013 | -130 | -67.52% |
| 2012 | -399 | 142.94% |
| 2011 | -164 | -7.79% |
| 2010 | -178 | 10.37% |
| 2009 | -161 | 172.03% |
| 2008 | -59.4 | 720.49% |
| 2007 | -7.23 | -98.54% |
| 2006 | -497 | 1052.86% |
| 2005 | -43.1 | 1680.87% |
| 2004 | -2.42 | -96.97% |
| 2003 | -80.0 | 263.64% |
| 2002 | -22.0 | -4.35% |
| 2001 | -23.0 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 15.2 | 32.99% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | 69.7 | 511.62% | 🇺🇸 USA |
 Amicus Therapeutics
FOLD | -15.4 | -235.42% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | -8.45 | -174.12% | 🇮🇱 Israel |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.